IL215404A0 - Anti-fcrh5 antibodies and immunoconjugates and methods of use - Google Patents
Anti-fcrh5 antibodies and immunoconjugates and methods of useInfo
- Publication number
- IL215404A0 IL215404A0 IL215404A IL21540411A IL215404A0 IL 215404 A0 IL215404 A0 IL 215404A0 IL 215404 A IL215404 A IL 215404A IL 21540411 A IL21540411 A IL 21540411A IL 215404 A0 IL215404 A0 IL 215404A0
- Authority
- IL
- Israel
- Prior art keywords
- immunoconjugates
- methods
- fcrh5 antibodies
- fcrh5
- antibodies
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21175409P | 2009-04-01 | 2009-04-01 | |
| US16621409P | 2009-04-02 | 2009-04-02 | |
| PCT/US2010/029521 WO2010114940A1 (en) | 2009-04-01 | 2010-03-31 | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL215404A0 true IL215404A0 (en) | 2011-12-29 |
Family
ID=42236394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215404A IL215404A0 (en) | 2009-04-01 | 2011-09-27 | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8362213B2 (enExample) |
| EP (1) | EP2414395A1 (enExample) |
| JP (2) | JP6099976B2 (enExample) |
| KR (1) | KR20120003478A (enExample) |
| CN (1) | CN102369218B (enExample) |
| AR (1) | AR076030A1 (enExample) |
| AU (1) | AU2010232682A1 (enExample) |
| BR (1) | BRPI1012560A2 (enExample) |
| CA (1) | CA2756988A1 (enExample) |
| CL (1) | CL2011002418A1 (enExample) |
| IL (1) | IL215404A0 (enExample) |
| MX (1) | MX2011010265A (enExample) |
| PE (1) | PE20120877A1 (enExample) |
| RU (2) | RU2016110891A (enExample) |
| SG (1) | SG174930A1 (enExample) |
| TW (1) | TW201039846A (enExample) |
| WO (1) | WO2010114940A1 (enExample) |
| ZA (1) | ZA201107128B (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011010264A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| BRPI1012560A2 (pt) | 2009-04-01 | 2016-07-26 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| DK2714684T3 (en) * | 2011-05-27 | 2018-11-26 | Ambrx Inc | COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| KR102626525B1 (ko) * | 2013-02-08 | 2024-01-19 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| MX364459B (es) | 2013-03-29 | 2019-04-26 | Sumitomo Dainippon Pharma Co Ltd | Vacuna de conjugado de péptido-antígeno de wt1. |
| US10588952B2 (en) | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
| AR096687A1 (es) * | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
| JP6208864B2 (ja) | 2013-06-24 | 2017-10-04 | エービーエルバイオ | 安定性が改善された抗体−薬物結合体およびこれの用途 |
| BR112016007736B1 (pt) | 2013-10-11 | 2022-09-27 | Mersana Therapeutics, Inc | Armação polimérica, e, composição farmacêutica |
| IL245009B (en) | 2013-10-11 | 2022-08-01 | Asana Biosciences Llc | Protein-polymer-drug conjugates |
| CA3131724A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| EP3191520B1 (en) | 2014-09-12 | 2020-01-01 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
| AU2015339012B2 (en) * | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| CN109072199B (zh) | 2014-12-05 | 2022-10-28 | 纪念斯隆-凯特琳癌症中心 | 靶向Fc受体样5的嵌合抗原受体及其用途 |
| AR104987A1 (es) * | 2015-06-15 | 2017-08-30 | Genentech Inc | Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| CN107849145B (zh) | 2015-06-16 | 2021-10-26 | 基因泰克公司 | 抗cd3抗体及其使用方法 |
| KR20250021639A (ko) | 2015-06-16 | 2025-02-13 | 제넨테크, 인크. | FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법 |
| CA3007115A1 (en) * | 2015-12-04 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and methods of use |
| JPWO2017188346A1 (ja) * | 2016-04-27 | 2019-02-28 | 国立大学法人 東京大学 | マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法 |
| KR20190039085A (ko) * | 2016-06-17 | 2019-04-10 | 마젠타 테라퓨틱스 인코포레이티드 | 세포의 고갈을 위한 조성물 및 방법 |
| KR20190074300A (ko) | 2016-11-15 | 2019-06-27 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 |
| JP7209963B2 (ja) | 2016-11-30 | 2023-01-23 | 住友ファーマ株式会社 | Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| WO2018237335A1 (en) * | 2017-06-23 | 2018-12-27 | VelosBio Inc. | IMMUNOCONJUGUATED ROR1 ANTIBODIES |
| WO2019020745A1 (en) | 2017-07-28 | 2019-01-31 | F. Hoffmann-La Roche Ag | Bispecific antibody formulation |
| FI3666787T3 (fi) | 2017-08-10 | 2024-03-15 | Sumitomo Pharma Co Ltd | Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja |
| US12018093B2 (en) | 2017-08-10 | 2024-06-25 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
| US10766613B2 (en) * | 2017-11-28 | 2020-09-08 | Textron Innovations Inc. | System and method for rotorcraft-weight-on-wheels flight state transition control |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| KR20200118065A (ko) | 2018-02-08 | 2020-10-14 | 제넨테크, 인크. | 이중특이적 항원-결합 분자 및 이의 사용 방법 |
| WO2019173503A2 (en) | 2018-03-06 | 2019-09-12 | Imcare Biotech, Llc | Serine protease inhibitor kazal (spik) compositions and methods |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020023106A1 (en) * | 2018-07-25 | 2020-01-30 | Northeastern University | Selectivity screening for antimicrobial compounds |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP7560255B2 (ja) * | 2019-02-13 | 2024-10-02 | 住友ファーマ株式会社 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
| JP7479302B2 (ja) * | 2019-02-13 | 2024-05-08 | 住友ファーマ株式会社 | ヘミアスタリン誘導体とその抗体薬物複合体 |
| CA3127312A1 (en) | 2019-02-13 | 2020-08-20 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin derivative having cysteine residue |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| SG11202108955QA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Antibody molecules that bind to nkp30 and uses thereof |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| WO2021007338A1 (en) | 2019-07-08 | 2021-01-14 | Imcare Biotech, Llc. | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
| WO2021050217A1 (en) | 2019-09-11 | 2021-03-18 | Imcare Biotech, Llc. | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| CR20220330A (es) | 2019-12-13 | 2022-08-04 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso. |
| JP2023507120A (ja) | 2019-12-18 | 2023-02-21 | テネオフォー， インコーポレイテッド | Ｃｄ３８に結合する重鎖抗体 |
| AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| MX2024005106A (es) | 2021-11-03 | 2024-07-02 | Affimed Gmbh | Ligandos biespecificos de cd16a. |
| CA3247428A1 (en) * | 2022-04-13 | 2023-10-19 | Hoffmann La Roche | Pharmaceutical compositions of therapeutic proteins and methods of use |
| WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CN116199772B (zh) * | 2022-11-16 | 2023-10-17 | 怡道生物科技(苏州)有限公司 | Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用 |
| WO2025235357A1 (en) | 2024-05-06 | 2025-11-13 | Rondo Therapeutics, Inc. | Bispecific antibodies that bind to cd28 and nectin-4 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| WO1995009864A1 (en) | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivative |
| US7074897B2 (en) | 1997-06-16 | 2006-07-11 | Genentech, Inc. | Pro943 polypeptides |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| ES2568625T3 (es) * | 1999-11-29 | 2016-05-03 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
| US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| EP1423428B2 (en) * | 2001-06-20 | 2012-11-14 | Fibron Ltd. | Antibodies that block fgfr3 activation, methods of screening for and uses thereof |
| WO2003024392A2 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| WO2004032828A2 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| ES2456325T3 (es) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| EP1696963A2 (en) | 2003-12-24 | 2006-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| US7999077B2 (en) | 2004-09-30 | 2011-08-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IRTA2 antibodies and methods of use |
| US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| CN101103042A (zh) * | 2005-01-12 | 2008-01-09 | 米德列斯公司 | Irta-2抗体及其用途 |
| SG155947A1 (en) * | 2005-06-20 | 2009-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| WO2008109533A2 (en) * | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
| BRPI1012560A2 (pt) | 2009-04-01 | 2016-07-26 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
| MX2011010264A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
-
2010
- 2010-03-31 BR BRPI1012560A patent/BRPI1012560A2/pt not_active IP Right Cessation
- 2010-03-31 EP EP10711526A patent/EP2414395A1/en not_active Ceased
- 2010-03-31 US US12/751,791 patent/US8362213B2/en not_active Expired - Fee Related
- 2010-03-31 AR ARP100101080A patent/AR076030A1/es not_active Application Discontinuation
- 2010-03-31 RU RU2016110891A patent/RU2016110891A/ru not_active Application Discontinuation
- 2010-03-31 AU AU2010232682A patent/AU2010232682A1/en not_active Abandoned
- 2010-03-31 SG SG2011069895A patent/SG174930A1/en unknown
- 2010-03-31 CN CN201080014347.1A patent/CN102369218B/zh not_active Expired - Fee Related
- 2010-03-31 PE PE2011001751A patent/PE20120877A1/es not_active Application Discontinuation
- 2010-03-31 KR KR1020117025849A patent/KR20120003478A/ko not_active Abandoned
- 2010-03-31 WO PCT/US2010/029521 patent/WO2010114940A1/en not_active Ceased
- 2010-03-31 MX MX2011010265A patent/MX2011010265A/es active IP Right Grant
- 2010-03-31 CA CA2756988A patent/CA2756988A1/en not_active Abandoned
- 2010-03-31 TW TW099109950A patent/TW201039846A/zh unknown
- 2010-03-31 JP JP2012503682A patent/JP6099976B2/ja not_active Expired - Fee Related
- 2010-03-31 RU RU2011144119/10A patent/RU2583270C2/ru not_active IP Right Cessation
-
2011
- 2011-09-27 IL IL215404A patent/IL215404A0/en unknown
- 2011-09-29 ZA ZA2011/07128A patent/ZA201107128B/en unknown
- 2011-09-30 CL CL2011002418A patent/CL2011002418A1/es unknown
-
2012
- 2012-11-09 US US13/673,565 patent/US9017951B2/en not_active Expired - Fee Related
-
2015
- 2015-08-27 JP JP2015168182A patent/JP2016028052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6099976B2 (ja) | 2017-03-29 |
| RU2583270C2 (ru) | 2016-05-10 |
| CA2756988A1 (en) | 2010-10-07 |
| AR076030A1 (es) | 2011-05-11 |
| US8362213B2 (en) | 2013-01-29 |
| CN102369218A (zh) | 2012-03-07 |
| JP2012522513A (ja) | 2012-09-27 |
| CL2011002418A1 (es) | 2012-03-16 |
| US9017951B2 (en) | 2015-04-28 |
| RU2016110891A (ru) | 2018-11-27 |
| HK1166805A1 (en) | 2012-11-09 |
| BRPI1012560A2 (pt) | 2016-07-26 |
| JP2016028052A (ja) | 2016-02-25 |
| PE20120877A1 (es) | 2012-08-06 |
| ZA201107128B (en) | 2012-12-27 |
| US20130089497A1 (en) | 2013-04-11 |
| WO2010114940A1 (en) | 2010-10-07 |
| KR20120003478A (ko) | 2012-01-10 |
| AU2010232682A1 (en) | 2011-11-10 |
| TW201039846A (en) | 2010-11-16 |
| EP2414395A1 (en) | 2012-02-08 |
| SG174930A1 (en) | 2011-11-28 |
| CN102369218B (zh) | 2014-07-16 |
| US20110171125A1 (en) | 2011-07-14 |
| MX2011010265A (es) | 2011-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2000026I1 (hu) | Anti-CD79b antitestek és immunkonjugátumok és alkalmazási eljárások | |
| IL215402A0 (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
| IL215404A0 (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
| ZA201005351B (en) | Anti-cd79b antibodies and immunoconjugates and methods of use | |
| IL215795A0 (en) | Anti-il-17f antibodies and methods of use thereof | |
| HUE042940T2 (hu) | Anti-FXI antitestek és alkalmazási eljárások | |
| IL250624B (en) | Anti-fgfr3 antibodies and methods of using them | |
| IL211623A0 (en) | Anti-notch2 antibodies and methods of use | |
| SI2516468T1 (sl) | Protitelesa proti flt3 in postopki uporabe istih | |
| EP2398494A4 (en) | Proproteins and their methods of use | |
| EP2464227A4 (en) | COMPOUNDS AND METHODS OF USE | |
| IL209754A0 (en) | Diazacarbazoles and methods of use | |
| IL236830A0 (en) | Diazahomoredene derivatives and methods of using them | |
| IL222514A0 (en) | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor | |
| IL214627A0 (en) | Humanized anti-cd20 antibodies and methods of use | |
| IL209548A0 (en) | Diazacarbazoles and methods of use | |
| ZA201300174B (en) | Anti-neuropilin antibodies and methods of use | |
| TH0901000138A (th) | แอนติ-cd79b แอนติบอดีและอิมมูโนคอนจูเกตและวิธีการใช้งาน |